T1	Participants 519 610	From February 1991 to December 1994, 376 patients with newly diagnosed CML in chronic phase
T2	Participants 636 688	340 patients were Ph/BCR-ABL positive and evaluable.
T3	Participants 938 1029	a total of 534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU).
T4	Participants 1104 1135	nontransplanted living patients
T5	Participants 1639 1651	534 patients
